Shaanxi Jiade/Huifeng Pharmaceutical was invited to participate in the “ICBC Empowers—Setting Sail for Overseas Expansion” Shaanxi Enterprise “Going Global” Financial Services Thematic Event.

On January 16, 2026, the Shaanxi Branch of the Industrial and Commercial Bank of China extended a formal invitation to Shaanxi Jiade Pharmaceutical & Health Products Group Co., Ltd. (hereinafter referred to as “Jiade Pharma”), cordially inviting the company’s finance or investment and financing executives to attend the “ICBC Empowers—Setting Sail for Overseas Expansion” Shaanxi Enterprise “Going Global” Financial Services Thematic Event. This event is jointly organized by the Shaanxi Provincial Department of Commerce and the Shaanxi Branch of the Industrial and Commercial Bank of China, aiming to bring together resources from government, enterprises, and banks, establish a high-end platform for exchange and cooperation, and help Shaanxi-based companies expand into international markets and deepen their participation in global cooperation. As the general distributor of Huifeng Pharmaceutical—a key manufacturer and exporter of pharmaceutical raw materials in Shaanxi Province—Jiade Pharma, with its internationally oriented strategy and strong industry influence in the pharmaceutical raw materials sector, has been invited to be one of the key participating enterprises at this event.

Leveraging our competitive edge in API exports to highlight the company’s core competitiveness.

• Huifeng Pharmaceutical was founded in 2002 and is headquartered in the Xi'an High-Tech Industrial Development Zone. Its factory is located in Changwu County, Xianyang, an area in northwest China that is rich in raw material resources and boasts a uniquely advantageous supply chain for raw materials. The company has long been dedicated to the R&D and production of plant extracts, pharmaceutical raw materials, and biopharmaceuticals. Its core products—the rutin and diosmin series—hold a significant market share globally and are exported to more than 20 countries and regions, including France, Spain, Germany, and the United States.
• The company has successively obtained numerous certifications, including ISO9001 quality system certification, national GMP certification, and European COS certification. It has also undertaken national high-tech demonstration projects and projects under the Ministry of Science and Technology’s Torch Program. Its technological strength and production standards have reached international levels. As a key export-oriented manufacturer in Shaanxi Province, Huifeng, with its stringent quality control system and stable production capacity, has become a benchmark enterprise in China’s active pharmaceutical ingredient (API) sector, particularly in the fields of rutin and diosmin.

Empowering Activities: Tackling the Pain Points of API Companies Going Global

• The event is scheduled to be held on January 27, 2026, at the Sofitel Hotel in the Xi'an People's Building. The agenda is closely tailored to meet the internationalization needs of active pharmaceutical ingredient (API) companies:

1. Policy and Financial Support: The Financial Markets Department of the ICBC Head Office will provide an in-depth analysis of the foreign exchange market situation, while experts from the Specialized Financing Department will elaborate on cross-border financing solutions, helping enterprises optimize their capital management. 
2. Opportunities for Regional Cooperation: Overseas institutions such as ICBC Indonesia and ICBC Moscow will introduce the business environment of target markets and help API exporters connect with overseas channels. 
3. Precise Bank-Business Matching: Through one-on-one consultations, we address practical issues faced by enterprises in cross-border trade, such as financing, settlement, and foreign exchange risk management.

• The representatives from Jiade/Huifeng Pharmaceutical attending the conference will engage in in-depth exchanges with experts from the Industrial and Commercial Bank of China’s headquarters and its overseas branches, as well as with colleagues from the pharmaceutical industry, to explore financial support pathways for active pharmaceutical ingredient (API) exports and further expand into key markets such as Europe and Southeast Asia.

Deepen cooperation among government, enterprises, and banks to boost industrial upgrading.

• This invitation to attend the conference represents an important step for Jiade Pharmaceutical in deepening its “technology + finance” strategy. Relying on the global service network of the Industrial and Commercial Bank of China, the company will accelerate the international deployment of its bulk pharmaceutical ingredient production capacity, thereby enhancing product added value and market competitiveness. At the same time, by participating in policy briefings and industry seminars, Jiade Pharmaceutical will help align Shaanxi’s pharmaceutical raw material industry with international standards, injecting new momentum into the region’s high-quality economic development.
• In the future, Huifeng Pharmaceutical will continue to deepen its expertise in the active pharmaceutical ingredient (API) sector, driven by technological innovation and supported by financial empowerment, thereby helping domestic pharmaceutical APIs gain a global foothold and fulfilling our corporate mission of “Sowing Greenness, Devoting to Health.”

Shaanxi Jiade Pharmaceutical and Health Products Group Co., Ltd.

January 28, 2026

- Time: January 27, 2026 (Tuesday), 8:30 a.m. to 5:00 p.m. 
- Location: Sofitel International Convention & Exhibition Center, Xi'an People's Building 
- Organizer: Shaanxi Provincial Department of Commerce, Industrial and Commercial Bank of China Shaanxi Branch 
- Co-organizers: Industrial and Commercial Bank of China Head Office Special Financing Department, ICBC Asia, ICBC Moscow, and other overseas institutions

Citation note: 
- The event agenda and financial support program are based on the content of the official invitation letter from ICBC.